Press Kit & Data — bioaccess®
Company facts, brand usage, and de-identified benchmark data for journalists, analysts, and sponsors covering first-in-human clinical trials in Latin America.
Company facts
- Brand name: bioaccess® (always lowercase "b", with the registered mark).
- Legal entity: IMH ASSETS CORP.
- Founded: 2010
- Headquarters: 1200 Brickell Ave., Suite 1950 #1034, Miami, FL 33131, USA
- Positioning: The First-in-Human CRO — built for the U.S. and Latin America.
- Scale: 50+ clients accelerated since founding, 50+ pre-qualified clinical sites, 10 Latin American countries.
- Co-founders: Dr. Pedro Martinez-Clark, MD (Chief Medical Officer) and Dr. William O'Neill, MD (Medical Director).
- Logo: Download PNG
Cite this data
Each sentence is drawn from the bioaccess® LATAM First-in-Human Benchmarks 2026 — de-identified planning benchmarks, not guarantees.
- Ethics-committee approval takes 4–8 weeks on the bioaccess® platform in Latin America, versus 6–12 months in the U.S. and E.U.
- Protocol to first patient runs 6–8 weeks on the bioaccess® Latin American platform, versus 6–12 months in the U.S. and E.U.
- Per-patient site cost on the bioaccess® Latin American platform is $15,000–$35,000, versus $40,000–$75,000 in the U.S. and E.U.
- Ophthalmology outpatient implant studies run at approximately $13,000 per patient in site clinical cost on the bioaccess® Latin American platform.
- Orthopedic surgical-implant (inpatient) studies run at approximately $25,000–$28,000 per patient in site clinical cost on the bioaccess® Latin American platform.
- Peripheral vascular / endovascular (cath-lab, device-heavy) studies run at approximately $23,000–$38,000 per patient in site clinical cost on the bioaccess® Latin American platform.
- In Mexico, regulatory startup through approval package starts at approximately $188,000 on the bioaccess® platform, excluding the sponsor's investigational device, trial insurance, and the study beyond approval.
- In Colombia, regulatory startup through approval package starts at approximately $305,000 on the bioaccess® platform — roughly 1.6× Mexico due to the additional INVIMA technical-dossier step (GICASE / Sala Especializada).
- In Panama, ethics approval on the bioaccess® platform lands in approximately 3–5 weeks via MINSA plus CNBI-registered committees — among the fastest in Latin America.
Source: bioaccess® LATAM First-in-Human Benchmarks 2026 — https://bioaccessla.com/latam-fih-benchmarks-2026
Downloadable dataset
Media contact
Media and analyst inquiries: jmclark@bioaccessla.com. General contact page.
